Incretin and Growth-Hormone Peptides: Appetite, Energy Balance, and Tissue Growth Mechanisms

Hello again. Last lesson established the taxonomy: GLP-1 analogues, dual incretins, GH itself, GHRH analogues, and ghrelin-pathway secretagogues are not interchangeable merely because they are all discussed as “peptides.” We also separated a plausible receptor mechanism from evidence of a worthwhile real-world outcome.

This lesson moves from labels to causal pathways. The central question is not simply whether an agent “burns fat” or “boosts metabolism,” but which term in energy balance it actually changes: appetite and food intake, energy expenditure, nutrient partitioning, or tissue signalling. That distinction is especially important when cutting while trying to retain muscle.

---

Energy balance: an accounting identity, not a marketing slogan

At the broadest level, body energy stores change according to:

$$\Delta E_{\mathrm{body}}=E_{\mathrm{intake}}-E_{\mathrm{expenditure}}$$

Energy expenditure itself has several components:

$$E_{\mathrm{expenditure}}=E_{\mathrm{rest}}+E_{\mathrm{activity}}+E_{\mathrm{thermic}}$$

where the terms are, approximately:

• Resting expenditure: energy needed to maintain organs and tissues at rest.
• Activity expenditure: deliberate exercise plus non-exercise movement.
• Thermic effect of food: digestion, absorption, and processing of nutrients.

This identity does not tell us why a person eats less, moves less, or has a lower resting expenditure. It does, however, give a disciplined way to inspect claims.

For example:

• A GLP-1 medicine can make a calorie deficit more achievable by reducing hunger, cravings, meal size, and sometimes the appeal of highly palatable food.
• A ghrelin-receptor agonist may increase GH secretion, but it can also increase hunger—potentially making a deficit harder to maintain.
• GH can increase release of fatty acids from adipose tissue, but fat mobilization is not automatically net fat loss.
• Losing body mass itself generally lowers expenditure. A smaller body costs less energy to move and maintain.

Three terms that are often blurred in fitness discussion should be kept distinct:

Term	What it means	What it does not establish
Lipolysis	Release of fatty acids from stored triglyceride	That those fatty acids were oxidized rather than re-stored
Fat oxidation	Using fat as fuel at a given time	That total fat mass must fall over weeks or months
Fat loss	A net reduction in adipose tissue over time	That resting metabolic rate increased

A compound can shift fuel use toward fat in the short term while total energy expenditure is unchanged or even lower. Conversely, a drug can lead to substantial fat loss mainly by reducing intake, with no meaningful “metabolic boost.”

---

Incretin medicines: primarily appetite and intake drugs

GLP-1 is an incretin hormone released after nutrient ingestion. Native GLP-1 is short-lived; medicines such as liraglutide and semaglutide are engineered to activate the GLP-1 receptor for much longer. Tirzepatide activates both the GIP and GLP-1 receptors.

Their glucose effects are important—particularly stimulation of insulin secretion in a glucose-dependent context—but better glycaemic control is not itself an explanation for fat loss. For body composition, the central mechanism is typically reduced energy intake.

GLP-1 receptor activation can affect eating through overlapping pathways:

1. Satiety and hunger signalling. GLP-1 receptors are present in brain regions involved in energy homeostasis, including the hypothalamus and hindbrain. Pharmacological GLP-1 receptor activation can increase fullness and reduce subjective hunger.

2. Food cue and reward processing. Human studies show altered responses to food cues in reward- and motivation-related brain regions. In practical terms, some people report less “food noise,” fewer cravings, or less pull toward highly palatable food. This is not a loss of free will, nor is it uniform across people; it is a shift in the conditions under which food decisions are made.

3. Gastric emptying and meal dynamics. GLP-1 can slow gastric emptying, particularly early in treatment, which can contribute to fullness. But delayed gastric emptying is not malabsorption: the calories are generally still absorbed. With chronic treatment, gastric-emptying effects may attenuate and do not explain the full weight-loss effect.

4. Adverse gastrointestinal experience. Nausea, vomiting, constipation, or diarrhoea can reduce food intake, especially during dose escalation. It would be simplistic to reduce all appetite effects to nausea, but it would be equally wrong to pretend gastrointestinal effects are irrelevant to intake or adherence.

The practical causal chain is therefore usually:

$$\text{GLP-1 receptor activation}\to \text{less hunger, greater satiety, altered food reward}\to \text{lower average energy intake}\to \text{weight and fat loss over time}$$

The medicine does not suspend energy balance. It changes the behavioural and physiological forces that normally make a sustained deficit difficult.

The “metabolic boost” claim fails a basic comparison

Weight loss is often accompanied by lower total energy expenditure. That is expected: there is less total mass to maintain and move. In addition, adaptive responses to energy restriction can reduce expenditure beyond what would be predicted from mass change alone.

Therefore, to claim that a medicine has raised metabolism in a meaningful way, it is not enough to observe that:

• brown adipose tissue takes up more glucose;
• resting expenditure does not fall as much as expected in a small study;
• fat oxidation rises transiently;
• someone feels more energetic; or
• the scale falls quickly.

The relevant test is whether the intervention produces a reliable, clinically meaningful increase in energy expenditure after accounting for the weight and body-composition change it caused.

For GLP-1 receptor agonists alone, human evidence does not support a large or reliable increase in resting metabolic rate. In the human studies discussed in the review, reductions in food intake are consistently the dominant mechanism. This matters for expectations: GLP-1 medicines can be highly effective for weight management without acting like a thermogenic stimulant.

---

Dual and triple incretins: more receptors do not automatically mean more metabolism

The diagram below is useful, provided you read its legend closely. Pink mouse icons denote rodent findings; black human icons denote human findings. It is therefore not a menu of equally established human effects.

Adding receptor targets can change the pharmacology, but it also increases the number of uncertainties.

GIP plus GLP-1: tirzepatide

Tirzepatide is a GIP/GLP-1 receptor agonist. Its weight-loss effects in humans are substantial, but it should not be described simply as “GLP-1 plus a metabolism booster.”

The GLP-1 component clearly contributes to appetite and intake reduction. GIP biology is more complex: GIP has roles in insulin secretion and is active in multiple tissues, including the brain. Precisely how much GIP agonism contributes to the additional weight loss relative to GLP-1 agonism alone remains an active mechanistic question.

The important practical conclusion is conservative: do not infer a major increase in total energy expenditure merely from dual agonism. Changes in fuel selection—for example, a greater fraction of energy derived from fat—are not the same as an increase in total calories expended.

Glucagon plus GLP-1: a more plausible thermogenic mechanism, but not a settled outcome

Glucagon is different. It is a counter-regulatory hormone that mobilizes energy stores and increases hepatic glucose production. Acute glucagon exposure can increase energy expenditure through energy-demanding liver processes, including gluconeogenesis, and may influence cardiac work and fat oxidation.

This gives GLP-1/glucagon co-agonists a more plausible route to affecting expenditure than GLP-1 agonism alone. But two cautions follow immediately:

• Acute physiology is not chronic body-composition evidence. A transient rise in expenditure during an infusion does not establish a durable increase over months.
• Catabolic signalling is not automatically desirable for a lifter in a deficit. A mechanism involving amino acids for gluconeogenesis, for example, may be in tension with muscle retention.

Triple agonists that add glucagon-receptor activity, such as investigational retatrutide, should therefore not be reduced to the slogan “more fat burning.” Their net effects depend on appetite, glycaemia, tolerability, expenditure, physical activity, and changes in both fat and fat-free mass.

---

The GH axis: fuel mobilization, growth signalling, and feedback

The GH axis is more difficult to reason about because it includes hormones with partially opposing actions and a strongly pulsatile release pattern.

The main pathways are:

• GHRH from the hypothalamus stimulates the anterior pituitary.
• Somatostatin inhibits GH release.
• The pituitary secretes GH in pulses.
• Ghrelin, produced largely in the stomach, can stimulate GH release through the ghrelin receptor.
• GH stimulates production of IGF-1, particularly in the liver, while also having direct effects in tissues.
• GH, IGF-1, and circulating free fatty acids feed back into the system.

A single GH blood test is difficult to interpret because secretion is pulsatile. IGF-1 is often more useful as an integrated marker of GH-axis activity over time, though it is not a direct real-time measure of GH exposure and certainly not proof of muscle gain.

GH and fat metabolism: mobilization is not free energy

GH has a lipolytic effect: it can promote release of non-esterified fatty acids from adipose tissue into the circulation. In fasting, this helps make stored energy available and may reduce reliance on glucose.

That does not mean GH “melts fat.” Released fatty acids have several possible fates:

• oxidation by muscle or other tissues;
• re-esterification and return to storage;
• conversion into other metabolic substrates.

For net fat loss, cumulative energy balance still matters. GH can alter nutrient partitioning and substrate availability, but it does not create an energy deficit by itself.

GH also has effects that can oppose insulin action, including reducing insulin sensitivity in some contexts and increasing hepatic glucose output. This is a reminder that “more lipolysis” is not synonymous with metabolically harmless or universally beneficial signalling.

GH, IGF-1, and tissue growth

In a growing child or adolescent, the GH–IGF-1 axis is central to linear growth, skeletal development, and tissue maturation. In a fully grown adult, once epiphyseal growth plates have fused, raising GH does not increase height.

In adults, the relevant mechanisms are instead:

• GH-mediated effects on lipid metabolism and tissue turnover;
• IGF-1-mediated growth and anabolic signalling;
• effects on connective tissue, bone, and extracellular fluid;
• local GH/IGF-related signalling in muscle, influenced by training and nutritional state.

This pathway gives GH a plausible connection to tissue growth. It does not establish that higher GH equals proportionally more contractile muscle hypertrophy in a trained adult.

A particularly important body-composition warning follows: fat-free mass is not synonymous with skeletal muscle. It includes water, organs, glycogen, bone-related compartments, and lean tissue. GH-related changes in extracellular fluid can therefore make a rapid increase in “lean mass” on a scan an unreliable proxy for new muscle protein.

GH secretagogues can have the wrong appetite effect for a cut

The class of drug matters:

Agent type	Main intervention point	Likely relevance to appetite
Recombinant GH	Supplies GH directly	Not primarily an appetite-control drug
GHRH analogue	Stimulates pituitary GH release	Not mainly used to suppress appetite
Ghrelin-receptor agonist / GHRP	Stimulates GH release through ghrelin-related signalling	Can increase hunger and food motivation
IGF-1	Acts downstream of GH	Growth-related signalling; not an appetite drug

This is why calling all GH-axis compounds “fat-loss peptides” is misleading. A ghrelin-pathway secretagogue might increase GH-axis activity yet make adherence to a calorie deficit harder by raising appetite. The net outcome cannot be inferred from the GH measurement alone.

---

A compact mechanism-versus-claim framework

Drug family	Demonstrated or plausible primary mechanism	What is not justified by mechanism alone
GLP-1 receptor agonists	Reduced hunger, increased satiety, lower energy intake; early slowing of gastric emptying	“They cause fat loss mainly by raising metabolism”
GIP/GLP-1 agonists	Strong weight reduction with GLP-1-mediated appetite effects; GIP may contribute through additional pathways	“Dual agonism proves a large energy-expenditure increase”
GLP-1/glucagon or triple agonists	Glucagon can acutely increase expenditure and alter hepatic fuel metabolism	“Any short-term thermogenic signal becomes a durable metabolic boost”
GH	Lipolysis, altered glucose and lipid metabolism, IGF-1-linked growth signalling	“Fat mobilization guarantees net fat loss”
GHRH or ghrelin-pathway secretagogues	Stimulation of endogenous GH release, with distinct feedback patterns	“Raising GH automatically builds muscle while cutting”
Ghrelin-receptor agonists	GH-axis stimulation plus hunger-related signalling	“A GH secretagogue is inherently compatible with appetite control”

For a bodybuilding-oriented cut, the cleanest causal model is:

1. Appetite control determines how feasible the energy deficit is.
2. Resistance training and adequate protein provide the principal non-drug signal for retaining muscle.
3. Rate of weight loss, sleep, training performance, and protein intake affect how much fat-free mass is retained.
4. Hormonal drugs may alter some of these constraints, but none eliminate the underlying trade-offs.

The next lesson will examine the human evidence that matters after mechanism: actual changes in weight, fat mass, and lean mass, alongside adverse effects and the substantial safety uncertainties that marketing language often omits.

---

Key takeaways

• GLP-1-based medicines primarily support weight loss by reducing hunger, cravings, and energy intake, not by creating a large increase in human resting metabolic rate.
• Slower gastric emptying can contribute to fullness, but it is not malabsorption and is not the full explanation for long-term weight loss.
• Rodent findings about brown fat and thermogenesis should not be casually presented as established human “metabolic boost” effects.
• Adding GIP or glucagon receptor activity changes the mechanism, but “more receptors” is not equivalent to “more metabolism.”
• Glucagon-containing agents have a more plausible acute route to increased expenditure, yet durable human effects and body-composition trade-offs require direct evidence.
• GH promotes lipolysis and signals through IGF-1, but released fatty acids are not automatically burned, and GH-axis activation is not synonymous with net fat loss or new skeletal muscle.
• Ghrelin-pathway GH secretagogues can increase appetite, making them conceptually poorly aligned with appetite control during a cut.
• When assessing a claim, ask: Does it alter intake, expenditure, substrate use, water balance, tissue signalling, or merely a biomarker?